KROS - Keros Therapeutics Inc - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4923271013
Blood Disorder, Cancer, Pulmonary Hypertension, Obesity, Neuromuscular Diseases
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for patients with disorders related to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins.
The company's lead product candidate, KER-050, is being developed to treat low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. These conditions can lead to severe fatigue, weakness, and increased risk of infections and bleeding.
In addition to KER-050, Keros Therapeutics is also developing KER-012, which is currently in Phase II clinical trials for the treatment of pulmonary arterial hypertension and cardiovascular disorders. Pulmonary arterial hypertension is a rare and debilitating condition characterized by high blood pressure in the lungs, leading to shortness of breath, fatigue, and limited exercise capacity.
The company is also investigating KER-065, which is in Phase I clinical trials for the treatment of obesity and neuromuscular diseases. Obesity is a major public health concern, and neuromuscular diseases, such as muscular dystrophy, can significantly impact quality of life.
Keros Therapeutics has established a collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. This partnership aims to accelerate the development and availability of KER-050 for patients in need.
Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts, and is committed to advancing its pipeline of novel therapeutics to improve the lives of patients with serious diseases. For more information, visit their website at https://www.kerostx.com.
Drawdown (Underwater) Chart
![Drawdown / Underwater Chart for KROS - Keros Therapeutics Inc - Stock & Dividends](https://www.valueray.com/images/drawdown_chart/KROS.NASDAQ_drawdown.png)
Overall Trend and Yearly Seasonality
![Drawdown / Underwater Chart for KROS - Keros Therapeutics Inc - Stock & Dividends](https://www.valueray.com/images/chart/KROS.NASDAQ_seasonality.png)
KROS Stock Overview
Market Cap in USD | 1,709m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2020-04-08 |
KROS Stock Ratings
Growth 5y | 39.8 |
Fundamental | - |
Dividend | 0.00 |
Rel. Performance vs Sector | -2.69 |
Analysts | 4.80/5 |
Fair Price Momentum | 48.49 USD |
Fair Price DCF | - |
KROS Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
KROS Growth Ratios
Growth 12m | 45.70% |
Growth Correlation 12m | 45% |
Growth Correlation 3m | 7% |
CAGR 5y | 24.26% |
CAGR/Mean DD 5y | 0.63 |
Sharpe Ratio 12m | 0.69 |
Alpha vs SP500 12m | 12.74 |
Beta vs SP500 5y weekly | 1.56 |
ValueRay RSI | 84.46 |
Volatility GJR Garch 1y | 58.95% |
Price / SMA 50 | 11.37% |
Price / SMA 200 | 2.94% |
Current Volume | 402.9k |
Average Volume 20d | 320.2k |
External Links for KROS Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of September 08, 2024, the stock is trading at USD 52.51 with a total of 402,859 shares traded.
Over the past week, the price has changed by +15.79%, over one month by +7.69%, over three months by +7.85% and over the past year by +43.82%.
According to ValueRays Forecast Model, KROS Keros Therapeutics Inc will be worth about 54.7 in September 2025. The stock is currently trading at 52.51. This means that the stock has a potential upside of +4.11%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 91.9 | 75.0 |
Analysts Target Price | 88.9 | 69.2 |
ValueRay Target Price | 54.7 | 4.11 |